The Latin America, Middle East and Africa Cell Therapy Market is expected to witness market growth of 31.8% CAGR during the forecast period (2020-2026).
Direct cell reprogramming has gained massive attention as a unique therapeutic strategy. This is due to the superior efficacy and security. A privately-owned company, Fortuna Fix is making efforts to become the first-ever company to begin clinical use of neural stem cells of patients, which will be generated by direct reprogramming for substitution of lost neuronal tissue in case of neurotrauma or neurodegeneration. These ongoing activities is expected to contribute to market development.
With considerable efforts and regulations being deployed to contain the spread of the COVID-19 crisis, the cell therapy market has been influenced to some degree. Improvement in ongoing research is a major concern, as the majority of universities across the world have reduced their enrollment process for clinical trials for all other research activities.
The arrival of modern technologies has encouraged the development of advanced cellular therapies growth. Companies are using the latest technologies with an aim to increase their product offerings and set-up out-licensing or co-development agreements with other bodies to encourage their product development programs.
The Brazil market dominated the LAMEA Non-Stem Cell Market by Country 2019, and is expected to continue to be a dominant market till 2026. The Argentina market is expected to witness a CAGR of 34.6% during (2020 - 2026). Additionally, The UAE market is exhibiting a CAGR of 33.6% during (2020 - 2026).
The Autologous market dominated the Saudi Arabia Cell Therapy Market by Therapy Type 2019, thereby, achieving a market value of $145.2 million by 2026. Additionally, The Allogeneic market is expected to witness highest CAGR of 35% during (2020 - 2026).
Based on Therapy Type, the market is segmented into Autologous and Allogeneic. Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.
Scope of the Study
Market Segments covered in the Report:
By Therapy Type
By Therapeutic Area
By End User
By Cell Type
By Country
Companies Profiled
Unique Offerings from the Publisher
Direct cell reprogramming has gained massive attention as a unique therapeutic strategy. This is due to the superior efficacy and security. A privately-owned company, Fortuna Fix is making efforts to become the first-ever company to begin clinical use of neural stem cells of patients, which will be generated by direct reprogramming for substitution of lost neuronal tissue in case of neurotrauma or neurodegeneration. These ongoing activities is expected to contribute to market development.
With considerable efforts and regulations being deployed to contain the spread of the COVID-19 crisis, the cell therapy market has been influenced to some degree. Improvement in ongoing research is a major concern, as the majority of universities across the world have reduced their enrollment process for clinical trials for all other research activities.
The arrival of modern technologies has encouraged the development of advanced cellular therapies growth. Companies are using the latest technologies with an aim to increase their product offerings and set-up out-licensing or co-development agreements with other bodies to encourage their product development programs.
The Brazil market dominated the LAMEA Non-Stem Cell Market by Country 2019, and is expected to continue to be a dominant market till 2026. The Argentina market is expected to witness a CAGR of 34.6% during (2020 - 2026). Additionally, The UAE market is exhibiting a CAGR of 33.6% during (2020 - 2026).
The Autologous market dominated the Saudi Arabia Cell Therapy Market by Therapy Type 2019, thereby, achieving a market value of $145.2 million by 2026. Additionally, The Allogeneic market is expected to witness highest CAGR of 35% during (2020 - 2026).
Based on Therapy Type, the market is segmented into Autologous and Allogeneic. Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.
Scope of the Study
Market Segments covered in the Report:
By Therapy Type
- Autologous
- Allogeneic
By Therapeutic Area
- Malignancies
- Autoimmune Disorders
- Musculoskeletal Disorders
- Dermatology
- Others
By End User
- Academic & Research Institutes
- Hospitals & Clinics
By Cell Type
- Stem Cell
- Umbilical Cord-Derived
- Adipose-Derived Stem Cell
- Non-Stem Cell
- Bone Marrow
- Blood
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Fujifilm Holdings Corporation
- Smith & Nephew PLC
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Medipost Co., Ltd.
- Stemedica Cell Technologies, Inc.
- NuVasive, Inc.
- Avantor, Inc.
- Vericel Corporation
- Pharmicell Co., Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Cell Therapy Market by Therapy Type
Chapter 5. LAMEA Cell Therapy Market by Therapeutic Area
Chapter 6. LAMEA Cell Therapy Market by End User
Chapter 7. LAMEA Cell Therapy Market by Cell Type
Chapter 8. LAMEA Cell Therapy Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Fujifilm Holdings Corporation
- Smith & Nephew PLC
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Medipost Co., Ltd.
- Stemedica Cell Technologies, Inc.
- NuVasive, Inc.
- Avantor, Inc.
- Vericel Corporation
- Pharmicell Co., Ltd.
Methodology
LOADING...
